Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Iron overload is the hallmark of hereditary hemochromatosis and a complication of iron-loading anemias such as β-thalassemia. Treatment can be burdensome and have significant side effects, and new therapeutic options are needed. Iron overload in hereditary hemochromatosis and β-thalassemia intermedia is caused by hepcidin deficiency. Although transgenic hepcidin replacement in mouse models of these diseases prevents iron overload or decreases its potential toxicity, natural hepcidin is prohibitively expensive for human application and has unfavorable pharmacologic properties. Here, we report the rational design of hepcidin agonists based on the mutagenesis of hepcidin and the hepcidin-binding region of ferroportin and computer modeling of their docking. We identified specific hydrophobic/aromatic residues required for hepcidin-ferroportin binding and obtained evidence in vitro that a thiol-disulfide interaction between ferroportin C326 and the hepcidin disulfide cage may stabilize binding. Guided by this model, we showed that 7–9 N-terminal amino acids of hepcidin, including a single thiol cysteine, comprised the minimal structure that retained hepcidin activity, as shown by the induction of ferroportin degradation in reporter cells. Further modifications to increase resistance to proteolysis and oral bioavailability yielded minihepcidins that, after parenteral or oral administration to mice, lowered serum iron levels comparably to those after parenteral native hepcidin. Moreover, liver iron concentrations were lower in mice chronically treated with minihepcidins than those in mice treated with solvent alone. Minihepcidins may be useful for the treatment of iron overload disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Minihepcidins are synthetic hepcidin agonists previously shown to bind ferroportin and induce its endocytosis and proteolysis, thus preventing iron overload in hepcidin-deficient mice (Preza et al., 2011; Ramos et al., 2012).”
From Hepcidin-Induced Hypoferremia Is a Critical Host Defense Mechanism against the Siderophilic Bacterium Vibrio vulnificus (2015) · cites this paper as Preza et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other interactions between FPN and hepcidin are either hydrophobic or depend on hepcidin amide backbone atoms, which is consistent with the relatively high tolerance of amino acid substitutions within hepcidin 40 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“This led to the development of mini-hepcidin analogs containing a minimal core of 7–9 N-terminal amino acids with a single cysteine, which suffice to trigger ferroportin internalization and degradation in cells and mice (Preza et al., 2011).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Preza et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: The Hepcidin-Binding Site on Ferroportin Is Evolutionarily Conserved
De Domenico, I., Nemeth, E., Nelson, J. M., Phillips, J. D., Ajioka, R. S., Kay, M. S., Kushner, J. P., Ganz, T., Ward, D. M., & Kaplan, J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.002 · Cited by 129
Self-citationRetractedHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Self-citationNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
Self-citationZDOCK: An initial‐stage protein‐docking algorithm
Chen, R., Li, L., & Weng, Z. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10389 · Cited by 1,393
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L. E., Franchini, P. L., Dubé, M.-P., Andres, L., MacFarlane, J., Sakellaropoulos, N., Politou, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1274 · Cited by 974 · cited 1×
“Discussion In hereditary hemochromatosis, hepcidin deficiency is a consequence of destructive mutations in the genes encoding hepcidin (24) or one of its regulators, HFE (3) (most common), transferrin receptor 2 (25), or hemojuvelin (26).”
BackgroundSelf-citationMutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis
Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., Loukopoulos, D., & Camaschella, C. (2003) · Nature Genetics · doi:10.1038/ng1053 · Cited by 860 · cited 1×
“Discussion In hereditary hemochromatosis, hepcidin deficiency is a consequence of destructive mutations in the genes encoding hepcidin (24) or one of its regulators, HFE (3) (most common), transferrin receptor 2 (25), or hemojuvelin (26).”
BackgroundSreerama, N., Venyaminov, S. Y. U., & Woody, R. W. (1999) · Protein Science · doi:10.1110/ps.8.2.370 · Cited by 708
Immunoassay for human serum hepcidin
Ganz, T., Olbina, G., Girelli, D., Nemeth, E., & Westerman, M. (2008) · Blood · doi:10.1182/blood-2008-02-139915 · Cited by 688
Self-citationThe RosettaDock server for local protein-protein docking
Lyskov, S., & Gray, J. J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn216 · Cited by 592
Suppression of hepcidin during anemia requires erythropoietic activity
Pak, M., Lopez, M. A., Gabayan, V., Ganz, T., & Rivera, S. (2006) · Blood · doi:10.1182/blood-2006-06-028787 · Cited by 472 · cited 1×
“Nonheme iron concentration was determined as described (44), using”
MethodSelf-citation
Cited by
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Self-citationGanz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
“Alanine scanning of this ferroportin loop identified additional residues critical for hepcidin binding (193).”
BackgroundInfluentialSelf-citationTaher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31822-6 · Cited by 807
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Hepcidin and the iron-infection axis
Drakesmith, H., & Prentice, A. M. (2012) · Science · doi:10.1126/science.1224577 · Cited by 686
Drakesmith, H., Nemeth, E., & Ganz, T. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.006 · Cited by 638
“model was reinforced by the rational design of 9-amino acid minihepcidins that were as potent as and more drug-like than hepcidin itself (Preza et al., 2011b; Ramos et al., 2012).”
MethodSelf-citationHepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis
Nemeth, E., & Ganz, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126493 · Cited by 540
“How the new structural model accom od tes other hepcidin agonists ranging from minihepcidin peptides [23] to small molecules [24] remains to be determined.”
BackgroundSelf-citationBrissot, P., Pietrangelo, A., Adams, P. C., de Graaff, B., McLaren, C. E., & Loréal, O. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.16 · Cited by 430
Hepcidin and Iron in Health and Disease
Nemeth, E., & Ganz, T. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-032816 · Cited by 457
Self-citationLiver iron sensing and body iron homeostasis
Wang, C.-Y., & Babitt, J. L. (2019) · Blood · doi:10.1182/blood-2018-06-815894 · Cited by 360
Iron overload in thalassemia: different organs at different rates
Taher, A. T., & Saliba, A. N. (2017) · Hematology · doi:10.1182/asheducation-2017.1.265 · Cited by 355
“Longacting hepcidin analogs (minihepcidins) have thus been developed to suppress iron absorption and are currently being investigated.(57) If and when minihepcidins reach the clinical realm, they could be potentially used alone or in combination with ICT to control iron overload.”
BackgroundStructure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms
Billesbølle, C. B., Azumaya, C. M., Kretsch, R. C., Powers, A. S., Gonen, S., Schneider, S., Arvedson, T., Dror, R. O., Cheng, Y., & Manglik, A. (2020) · Nature · doi:10.1038/s41586-020-2668-z · Cited by 344
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Aschemeyer, S., Qiao, B., Stefanova, D., Valore, E. V., Sek, A. C., Ruwe, T. A., Vieth, K. R., Jung, G., Casu, C., Rivella, S., et al. (2018) · Blood · doi:10.1182/blood-2017-05-786590 · Cited by 325
Self-citationHepcidin-Induced Endocytosis of Ferroportin Is Dependent on Ferroportin Ubiquitination
Qiao, B., Sugianto, P., Fung, E., del-Castillo-Rueda, A., Moran-Jimenez, M.-J., Ganz, T., & Nemeth, E. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.018 · Cited by 334
“Human Fpn is thought to have a total of 14 or 15 cytoplasmic lysines (Liu et al., 2005; Rice et al., 2009), C with our previous study (Preza et al., 2011) supporting the model with 14 lysines.”
BackgroundResultSelf-citationNon-transfusion-dependent thalassemias
Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2013) · Haematologica · doi:10.3324/haematol.2012.066845 · Cited by 326
Anemia: progress in molecular mechanisms and therapies
Sankaran, V. G., & Weiss, M. J. (2015) · Nature Medicine · doi:10.1038/nm.3814 · Cited by 281
Iron and liver fibrosis: Mechanistic and clinical aspects
Mehta, K. J., Farnaud, S. J., & Sharp, P. A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i5.521 · Cited by 269
The Role of Iron and Iron Overload in Chronic Liver Disease
Milic, S., Mikolasevic, I., Orlic, L., Devcic, E., Starcevic-Cizmarevic, N., Stimac, D., Kapovic, M., & Ristic, S. (2016) · Medical Science Monitor · doi:10.12659/msm.896494 · Cited by 241
“Unlike hepatocytes, macrophages are relatively resistant to iron-related oxidative stress [8,66].”
BackgroundArezes, J., Jung, G., Gabayan, V., Valore, E., Ruchala, P., Gulig, P. A., Ganz, T., Nemeth, E., & Bulut, Y. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2014.12.001 · Cited by 227
“Serum samples were obtained from Hamp1-/- mice kept on an iron-poor or standard diet for 4-6 weeks and injected 24 h and 3 h before blood collection with 100 nmoles PR73 in SL220 or with SL220 only (5 mice per group).”
BackgroundMethodInfluentialSelf-citationFuqua, B. K., Vulpe, C. D., & Anderson, G. J. (2012) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2012.03.015 · Cited by 241
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice
Guo, S., Casu, C., Gardenghi, S., Booten, S., Aghajan, M., Peralta, R., Watt, A., Freier, S., Monia, B. P., & Rivella, S. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66969 · Cited by 222
Anderson, E. R., & Shah, Y. M. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120016 · Cited by 219
Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis
Ramos, E., Ruchala, P., Goodnough, J. B., Kautz, L., Preza, G. C., Nemeth, E., & Ganz, T. (2012) · Blood · doi:10.1182/blood-2012-07-440743 · Cited by 213
Self-citationZhao, N., Zhang, A.-S., & Enns, C. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67225 · Cited by 209
“104, 105, and Table 2).”
Molecular basis of β thalassemia and potential therapeutic targets
Thein, S. L. (2018) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2017.06.001 · Cited by 209
“Several genes involved in iron homeostasis have now been characterized, including those encoding HFE (HFE), transferrin receptor 2 (TfR2), ferroportin (FPN), hepcidin (HAMP) and hemojuvelin (HJV) [78].”
Schmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt, B. R., Hettinger, J., Bumcrot, D., & Fleming, M. D. (2013) · Blood · doi:10.1182/blood-2012-09-453977 · Cited by 204
Current status of beta‐thalassemia and its treatment strategies
Ali, S., Mumtaz, S., Shakir, H. A., Khan, M., Tahir, H. M., Mumtaz, S., Mughal, T. A., Hassan, A., Kazmi, S. A. R., Sadia, et al. (2021) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1788 · Cited by 201
“Synthesized miniature- hepcidin that has a longer half- life when orally given to mice showed a reduction in absorption of iron in mice and also has been recommended as prospective useful mediators in severe β- thalassemia patient (Preza et al., 2011).”
BackgroundPhysiology and pathophysiology of iron in hemoglobin-associated diseases
Coates, T. D. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.039 · Cited by 181
Pathophysiology and Clinical Manifestations of the -Thalassemias
Nienhuis, A. W., & Nathan, D. G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011726 · Cited by 180
“Synthetic mini-hepcidins with a longer half-life have been shown to reduce iron absorption in mice after oral administration and have been proposed as potential therapeutic agents in individuals with severe b-thalassemia (Preza et al. 2011).”
BackgroundIneffective erythropoiesis and regulation of iron status in iron loading anaemias
Camaschella, C., & Nai, A. (2016) · British Journal of Haematology · doi:10.1111/bjh.13820 · Cited by 172
“Hepcidin mimics corresponding to the 9 N-terminal amino acids of the mature 25 amino acid peptide (‘minihepcidins’) have been synthesized and modified for therapeutic use (Preza et al, 2011).”
MethodThe Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders
Ganz, T., & Nemeth, E. (2011) · Hematology · doi:10.1182/asheducation-2011.1.538 · Cited by 172
Self-citationMinihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676742 · Cited by 148
“minihepcidin prevented iron overload and caused partial redistribution of iron from the liver to the spleen.(17,18) Minihepcidins caused dose-dependent inhibition of intestinal iron absorption and, at higher doses, restricted the iron supply to erythropoiesis.”
BackgroundCappellini, M. D., Porter, J. B., Viprakasit, V., & Taher, A. T. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.001 · Cited by 182
“Mini-hepcidins are short peptides that mimic the activity of endogenous hepcidin [139].”
BackgroundMammalian iron transporters: Families SLC11 and SLC40
Montalbetti, N., Simonin, A., Kovács, G., & Hediger, M. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.002 · Cited by 161
“These results initiated the search for hepcidin agonists known as minihepcidins (Preza et al., 2011).”
BackgroundPharmacological Targeting of the Hepcidin/Ferroportin Axis
Sebastiani, G., Wilkinson, N., & Pantopoulos, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00160 · Cited by 127
The pathophysiology and pharmacology of hepcidin
Ruchala, P., & Nemeth, E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.004 · Cited by 140
“Mechanistically, hepcidin binding to ferroportin relies on the extracellular loop of ferroportin that contains sulfhydryl Cys326 residue and surrounding hydrophobic residues [47].”
BackgroundInfluentialSelf-citationMcKie, A. T., & Simpson, R. J. (2012) · Iron Physiology and Pathophysiology in Humans · doi:10.1007/978-1-60327-485-2_6 · Cited by 132
Hepcidin agonists as therapeutic tools
Casu, C., Nemeth, E., & Rivella, S. (2018) · Blood · doi:10.1182/blood-2017-11-737411 · Cited by 128
Self-citationHepcidin: A Promising Therapeutic Target for Iron Disorders A Systematic Review
Liu, J. L., Sun, B., Yin, H.-J., & Liu, S. (2016) · Medicine · doi:10.1097/md.0000000000003150 · Cited by 156
“Serum iron was reduced after chronic administration of retro-inverso mini-hepcidin in Hamp / mice.(86) Furthermore, an optimized mini-hepcidin named PR65 was chosen to”
MethodInfluentialHepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection
Frost, J. N., Tan, T. K., Abbas, M., Wideman, S. K., Bonadonna, M., Stoffel, N. U., Wray, K., Kronsteiner, B., Smits, G. P., Campagna, D. R., et al. (2020) · Med · doi:10.1016/j.medj.2020.10.004 · Cited by 142
The Liver in Regulation of Iron Homeostasis
Rishi, G., & Subramaniam, V. N. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00004.2017 · Cited by 124
“There has also been an interest in targeting the hepcidinferroportin axis itself using hepcidin mimics called “minihepcidins” (7, 68, 72).”
BackgroundManipulation of the hepcidin pathway for therapeutic purposes
Fung, E., & Nemeth, E. (2013) · Haematologica · doi:10.3324/haematol.2013.084624 · Cited by 123
Self-citationRivella, S. (2015) · Haematologica · doi:10.3324/haematol.2014.114827 · Cited by 123
Systemic iron homeostasis and erythropoiesis
Papanikolaou, G. V., & Pantopoulos, K. (2017) · IUBMB Life · doi:10.1002/iub.1629 · Cited by 146
“Even though these bonds determine the folding and structure of hepcidin, they appear to be redundant for iron regulation, since a minihepcidin consisting of the N-terminal fragment DTHFPICIF retains ferroportin-binding activity and promotes ferroportin degradation in cells and mice (39).”
BackgroundTaniguchi, R., Kato, H. E., Font, J., Deshpande, C. N., Wada, M., Ito, K., Ishitani, R., Jormakka, M., & Nureki, O. (2015) · Nature Communications · doi:10.1038/ncomms9545 · Cited by 120
Katsarou, A., & Pantopoulos, K. (2018) · Pharmaceuticals · doi:10.3390/ph11040127 · Cited by 112
“By contrast, ri-hep9 and palmitoyl-ri-hep9 promoted hypoferremia, while high doses of the latter had almost the same effect on serum iron levels to equivalent doses of full-length hepcidin [83].”
BackgroundProgesterone receptor membrane component-1 regulates hepcidin biosynthesis
Li, X., Rhee, D. K., Malhotra, R., Mayeur, C., Hurst, L. A., Ager, E., Shelton, G., Kramer, Y., McCulloh, D., Keefe, D., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83831 · Cited by 112
“Synthetic hepcidin peptides decrease iron levels in mice and have been developed for the treatment of hemochromatosis, although they are not currently in clinical use (16, 18).”
BackgroundIron and hepcidin: a story of recycling and balance
Camaschella, C. (2013) · Hematology · doi:10.1182/asheducation-2013.1.1 · Cited by 112
Ceruloplasmin-ferroportin system of iron traffic in vertebrates
Musci, G. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i2.204 · Cited by 108
Li, L.-X., Guo, F., Liu, H., & Zeng, T. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04239-9 · Cited by 122
“A short lipophilic hepcidin mimic called mini-hepcidin (PR65) significantly reduced liver and heart iron levels in a mouse model of iron overload [147, 148].”
BackgroundDiaminodiacid Bridges to Improve Folding and Tune the Bioactivity of Disulfide‐Rich Peptides
Guo, Y., Sun, D., Wang, F., He, Y., Liu, L., & Tian, C. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500699 · Cited by 104
The iron-regulatory hormone hepcidin: A possible therapeutic target?
Rochette, L., Gudjoncik, A., Guénancia, C., Zeller, M., Cottin, Y., & Vergely, C. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.004 · Cited by 117
Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia
Manolova, V., Nyffenegger, N., Flace, A., Altermatt, P., Varol, A., Doucerain, C., Sundstrom, H., & Dürrenberger, F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129382 · Cited by 98
“Orally bioavailable minihepcidins have been 78 shown to lower serum iron in wild-type mice (21).”
BackgroundHepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia
Michels, K. R., Zhang, Z., Bettina, A. M., Cagnina, R. E., Stefanova, D., Burdick, M. D., Vaulont, S., Nemeth, E., Ganz, T., & Mehrad, B. (2017) · JCI Insight · doi:10.1172/jci.insight.92002 · Cited by 93
“We used a previously described synthetic peptide based on the 9 N-terminal amino acids of the hepcidin molecule, which are necessary and sufficient to induce the degradation of ferroportin (37, 38).”
MethodSelf-citationPathophysiology and treatment of patients with beta-thalassemia – an update
Fibach, E., & Rachmilewitz, E. A. (2017) · F1000Research · doi:10.12688/f1000research.12688.1 · Cited by 108
“This was demonstrated in murine models of β -thal intermedia by (A) minihep-cidins, small peptides that mimic hepcidin activity and act as agonists 41 , (B) inhibition of negative regulators of matriptase-2 (TMPRSS6), a key regulator of hepcidin production, with silencing RNAs or antisense…”
BackgroundCancer cells with irons in the fire
Bystrom, L. M., & Rivella, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.04.035 · Cited by 89
Ehsani, S. (2020) · Biology Direct · doi:10.1186/s13062-020-00275-2 · Cited by 99
“It should be mentioned, however, that ‘mini-hepcidins’ conjugated to palmitoyl groups have been synthesized and studied previously [106], but these do not occur naturally.”
BackgroundOxidative Stress in β-Thalassemia
Fibach, E., & Dana, M. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0373-5 · Cited by 106
Structural basis of ion transport and inhibition in ferroportin
Pan, Y., Ren, Z., Gao, S., Shen, J., Wang, L., Xu, Z., Yu, Y., Bachina, P., Zhang, H., Fan, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19458-6 · Cited by 81
Agarwal, A. K., & Yee, J. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.04.005 · Cited by 99
β-Thalassemia intermedia: a comprehensive overview and novel approaches
Asadov, C. D., Alimirzoyeva, Z., Mammadova, T., Aliyeva, G., Gafarova, S., & Mammadov, J. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2411-9 · Cited by 94
High-throughput screening of small molecules identifies hepcidin antagonists
Fung, E., Sugianto, P., Hsu, J., Damoiseaux, R., Ganz, T., & Nemeth, E. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.083428 · Cited by 78
“Our previous study (Preza et al., 2011) demonstrated that, in addition to the thioldisulfide interaction between hepcidin and Fpn, the ligandreceptor binding also depends on the interaction of neighboring aromatic residues.”
BackgroundResultInfluentialSelf-citationBoyle, J. J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328356b145 · Cited by 77
NRF2 and Hypoxia-Inducible Factors: Key Players in the Redox Control of Systemic Iron Homeostasis
Duarte, T. L., Talbot, N. P., & Drakesmith, H. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8148 · Cited by 78
“Treatment of Hbb (th3/ + ) mice with minihepcidins, which are hepcidin agonists known to prevent iron overload in murine models of hemochromatosis (120, 124), improves ineffective erythropoiesis, anemia, and iron overload (21).”
Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease
Sheetz, M., Barrington, P., Callies, S., Berg, P. H., McColm, J., Marbury, T., Decker, B., Dyas, G. L., Truhlar, S. M. E., Benschop, R., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13877 · Cited by 76
“The ability of this mAb to block hepcidin's interaction with ferroportin would not be necessarily predicted by previous studies that identify loop 4 as the hepcidin binding loop.(42,43) LY2928057, which binds to loop 5, may be sterically inhibiting hepcidin's ability to bind to ferroportin on loop 4 or alternatively,…”
BackgroundTherapeutic potential of hepcidin − the master regulator of iron metabolism
Vyoral, D., & Petrák, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.010 · Cited by 85
Maternal hepcidin determines embryo iron homeostasis in mice
Sangkhae, V., Fisher, A. L., Chua, K. J., Ruchala, P. P., Ganz, T., & Nemeth, E. (2020) · Blood · doi:10.1182/blood.2020005745 · Cited by 81
Self-citationWhat can we learn from ineffective erythropoiesis in thalassemia?
Oikonomidou, P. R., & Rivella, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.10.001 · Cited by 79
di Patti, M. C. B., Cutone, A., Polticelli, F., Rosa, L., Lepanto, M. S., Valenti, P., & Musci, G. (2018) · BioMetals · doi:10.1007/s10534-018-0087-5 · Cited by 68
“Modeling of the hepcidin–Fpn interaction suggested that Cys326 is involved in a thiol-dependent interaction with hepcidin, perhaps involving the disulfide framework of hepcidin, while Phe324 and Tyr333 may form crucial contacts with two phenylalanine residues on the hepcidin moiety (Preza et al. 2011).”
InfluentialHepcidin and its therapeutic potential in neurodegenerative disorders
Qian, Z., & Ke, Y. (2019) · Medicinal Research Reviews · doi:10.1002/med.21631 · Cited by 65
“They discovered specific hydrophobic/aromatic residues required for hepcidin‐Fpn1 binding and obtained evidence in vitro that a thiol‐disulfide interaction between Fpn1 C326 and the hepcidin disulfide cage may stabilize binding.(243) They showed that S‐vinyl‐derivatization of minihepcidin(s) may be a suitable approach…”
BackgroundCHEN, B., Li, G., Shen, Y., Huang, X., & Xu, Y. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2484 · Cited by 68
“An artificial, biologically active form of hepcidin, known as ʻminihepcidinʼ, has been developed by Preza et al (56).”
Le Gac, G., Ka, C., Joubrel, R., Gourlaouen, I., Lehn, P., Mornon, J.-P., Férec, C., & Callebaut, I. (2013) · Human Mutation · doi:10.1002/humu.22369 · Cited by 63
“, 2005), and it is probable that some residues outside ES4 also interact with hepcidin [Preza et al., 2011].”
BackgroundGelderman, M. P., Baek, J. H., Yalamanoglu, A., Puglia, M., Vallelian, F., Burla, B., Vostal, J., Schaer, D. J., & Buehler, P. W. (2015) · Haematologica · doi:10.3324/haematol.2014.117325 · Cited by 63
Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis
Hawula, Z. J., Wallace, D. F., Subramaniam, V. N., & Rishi, G. (2019) · Pharmaceuticals · doi:10.3390/ph12040170 · Cited by 65
2021 update on clinical trials in β‐thalassemia
Musallam, K. M., Bou‐Fakhredin, R., Cappellini, M. D., & Taher, A. T. (2021) · American Journal of Hematology · doi:10.1002/ajh.26316 · Cited by 74
Modulation of hepcidin to treat iron deregulation: potential clinical applications
Blanchette, N. L., Manz, D. H., Torti, F. M., & Torti, S. V. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1124757 · Cited by 59
“developed.[79] These are small 7–9 amino acid peptides that mimic hepcidin function both in vitro and in vivo and were designed to retain the amino acids that were critical for Fpn binding.”
BackgroundZhang, V., Nemeth, E., & Kim, A. (2019) · Pharmaceuticals · doi:10.3390/ph12010030 · Cited by 57
“Studies in mice have shown that hepcidin mimetics are effective in lowering systemic iron and modulating the virulence and mortality of gram-negative pneumonia [5,76].”
BackgroundSelf-citationMatos, L. C., Batista, P., Monteiro, N., Simões, M. J., Egas, C., Pereira, J., Pinho, H., Santos, N., Ribeiro, J. P., Cipriano, M. A., et al. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328355cfd0 · Cited by 58
Cellular Catabolism of the Iron-Regulatory Peptide Hormone Hepcidin
Preza, G. C., Pinon, R., Ganz, T., & Nemeth, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058934 · Cited by 56
“As disulfide exchange is promoted at alkaline pH, this observation is consistent with our previous work showing thiol-disulfide interaction between hepcidin and ferroportin [7,8].”
BackgroundResultSelf-citationDiagnosis and treatment of hereditary hemochromatosis: an update
Kanwar, P., & Kowdley, K. V. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2013.816114 · Cited by 60
Ferristatin II Promotes Degradation of Transferrin Receptor-1 In Vitro and In Vivo
Byrne, S. L., Buckett, P. D., Kim, J., Luo, F., Sanford, J. C., Chen, J., Enns, C. A., & Wessling‐Resnick, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070199 · Cited by 60
“Several other pharmacological tools now have been developed to target the hepcidin axis [75], including ‘‘mini-hepcidins’’ that down-regulate ferroportin [76,77], BMP inhibitors that block Smad signaling [78,79], and agents that perturb Stat signaling Figure 6.”
Callebaut, I., Joubrel, R., Pissard, S., Kannengiesser, C., Gerolami, V., Ged, C., Cadet, E., Cartault, F., Ka, C., Gourlaouen, I., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu160 · Cited by 54
“(22, 24), which is consistent with the hepcidin resistance”
BackgroundDekan, Z., Mobli, M., Pennington, M. W., Fung, E., Nemeth, E., & Alewood, P. F. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201310103 · Cited by 53
Self-citationIron overload cardiomyopathy: Using the latest evidence to inform future applications
Kumfu, S., Chattipakorn, S. C., & Chattipakorn, N. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221076397 · Cited by 55
Casu, C., Chessa, R., Liu, A., Gupta, R., Drakesmith, H., Fleming, R., Ginzburg, Y. Z., MacDonald, B., & Rivella, S. (2020) · Haematologica · doi:10.3324/haematol.2018.212589 · Cited by 50
“Minihepcidins function as hepcidin agonists, target ferroportin, and reduce iron absorption and transferrin saturation.(23,24) We and others showed that administration of minihepcidins or agents that induce hepcidin expression in Hbb mice decreased transferrin saturation, heme synthesis, hemichrome formation, and impr…”
BackgroundLiver Iron Loading in Alcohol-Associated Liver Disease
Ali, N., Ferrao, K., & Mehta, K. J. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.08.010 · Cited by 62
A structural model of human ferroportin and of its iron binding site
Bonaccorsi di Patti, M. C., Polticelli, F., Cece, G., Cutone, A., Felici, F., Persichini, T., & Musci, G. (2014) · The FEBS Journal · doi:10.1111/febs.12825 · Cited by 44
Inflammation, dysregulated iron metabolism, and cardiovascular disease
Rosenblum, S. L. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1124178 · Cited by 61
The Role of Iron Metabolism in Lung Inflammation and Injury
Kim, J., & Wessling-Resnick, M. (2012) · Journal of Allergy & Therapy · doi:10.4172/2155-6121.s4-004 · Cited by 58
“For example, inhibitors of these transporters [99-101] might help decrease iron-associated cellular damage.”
Czaja, A. J. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15173 · Cited by 55
“The N‐terminus of the hepcidin molecule is critical for binding with ferroportin, 281 and stable, truncated, bioactive derivatives of hepcidin containing the critical 7‐9 amino acid motif at the N‐terminus can inhibit ferroportin.(279) These engineered peptides that have been TABLE 3 Evolving management strategies for…”
BackgroundModulation of Hepcidin as Therapy for Primary and Secondary Iron Overload Disorders
Schmidt, P. J., & Fleming, M. D. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.11.004 · Cited by 42
Kowdley, K. V., Modi, N. B., Peltekian, K. M., Vierling, J. M., Ferris, C. D., Valone, F. H., & Gupta, S. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00250-9 · Cited by 51
Hamp1 but not Hamp2 regulates ferroportin in fish with two functionally distinct hepcidin types
Neves, J. V., Ramos, M. F., Moreira, A. C., Silva, T., Gomes, M. S., & Rodrigues, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-14933-5 · Cited by 45
Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology
Vela, D. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.111 · Cited by 44
Garcia‐Santos, D., Hamdi, A., Saxova, Z., Fillebeen, C., Pantopoulos, K., Horváthová, M., & Ponka, P. (2017) · Blood · doi:10.1182/blood-2017-07-798728 · Cited by 42
Iron-tracking strategies: Chaperones capture iron in the cytosolic labile iron pool
Philpott, C. C., Protchenko, O. V., Wang, Y., Novoa‐Aponte, L., León-Torres, A., Grounds, S., & Tietgens, A. J. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1127690 · Cited by 48
“Minihepcidin is a synthetic peptide which contains the 9Nterminal amino acids of human hepcidin (Preza et al., 2011; Ramos et al., 2012).”
BackgroundLua, R. C., Wilson, S. J., Konecki, D. M., Wilkins, A. D., Venner, E., Morgan, D. H., & Lichtarge, O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1279 · Cited by 38
Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
Bou‐Fakhredin, R., Bazarbachi, A. H., Chaya, B. F., Sleiman, J., Cappellini, M. D., & Taher, A. T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122778 · Cited by 44
Metadata
- Authors
- Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E.
- Affiliations
- University of California, Los Angeles (US)
- Columbia University (US)
- California Institute of Technology (US)
- University of California, Irvine (US)
- Corresponding author
- Nemeth, Elizabeta
- Venue
- Journal of Clinical Investigation
- Published
- 2011-12-01
- Volume
- 121
- Issue
- 12
- Pages
- 4880-4888
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3225996
- OpenAlex
- W2146444665
- Cited by
- 234
- References
- 45
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 11 · 2023: 15 · 2022: 18 · 2021: 12 · 2020: 16 · 2019: 15 · 2018: 12 · 2017: 29 · 2016: 18 · 2015: 20 · 2014: 13 · 2013: 22 · 2012: 17
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Funders
- National Institutes of Health
- Center for AIDS Research, University of Washington
- University of California, Irvine
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065029, R01DK082717)
- Jonsson Comprehensive Cancer Center
- California NanoSystems Institute
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- iron overload, hereditary hemochromatosis, beta-thalassemia intermedia, ferroportin, oral bioavailability, serum iron, liver iron, peptide design
- MeSH terms
- Ferroportin, Amino Acid Sequence, Animals, Binding Sites, Computer Simulation, Cysteine, Drug Evaluation, Preclinical, Humans, Iron, Liver, Models, Molecular, Molecular Sequence Data, Peptide Fragments, Protein Conformation, Structure-Activity Relationship, Drug Design, Mutagenesis, Site-Directed, Iron Overload, Amino Acid Substitution, Antimicrobial Cationic Peptides, Protein Interaction Mapping, Cation Transport Proteins, Mice, Hydrophobic and Hydrophilic Interactions, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.